Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a key milestone in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital. The company announced that patient enrollment has reached the halfway mark, and preliminary imaging data show encouraging signals in acute MS lesions, as well as potential sensitivity to gray matter lesions. This progress is significant because it evaluates a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which could enhance the development of MS therapies.
The study aims to validate an imaging biomarker that could be used to monitor treatment efficacy in clinical trials. Quantum BioPharma believes this approach could be particularly valuable for its investigational candidate Lucid-MS, for which an IND submission for a Phase 2 trial was submitted to the FDA in March 2026. The ability to directly visualize demyelination in the brain could provide a more objective measure of drug effect than traditional clinical scales.
Multiple sclerosis affects approximately 2.8 million people worldwide, and current imaging techniques have limitations in detecting gray matter lesions, which are increasingly recognized as important contributors to disability. The [¹⁸F]3F4AP tracer targets potassium channels exposed during demyelination, potentially allowing for earlier and more accurate detection of active lesions.
This announcement comes at a critical time for the company, as it advances its pipeline of treatments for neurodegenerative and metabolic disorders. Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions, with its lead compound Lucid-MS showing promise in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
The company also retains an interest in Unbuzzd Wellness Inc., with a royalty agreement that includes payments of 7% of sales until $250 million is reached, then dropping to 3% in perpetuity. For more information, visit the company's newsroom at https://ibn.fm/QNTM.
The full press release is available at https://ibn.fm/4IZ0y. This development underscores the potential of novel imaging biomarkers to transform MS clinical trials and patient care.
